Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) is a medical technology company focused on advancing the surgical management of bunion and related midfoot deformities. As a commercial‑stage orthopaedic device company with a portfolio centered on 3D bunion correction, Treace regularly issues news on product innovation, clinical evidence, financial performance and capital structure.
On this page, readers can follow TMCI news covering quarterly and annual financial results, revenue trends, liquidity updates and guidance changes, as reported in the company’s earnings releases and related Form 8‑K filings. These updates often discuss factors such as surgeon adoption of Treace’s expanded bunion technology portfolio, procedure volume dynamics and the impact of broader economic conditions on elective bunion surgery.
Treace also announces new technologies and product milestones, including developments in its Lapiplasty 3D Bunion Correction System, minimally invasive systems such as Nanoplasty and Percuplasty, the SpeedMTP MTP Fusion System, SpeedPlate rapid compression implants and IntelliGuide patient specific planning and cut guide technology. News items may highlight first surgical cases with new platforms, transitions from limited market release to full market release and surgeon feedback on workflow and clinical use.
In addition, TMCI news includes updates on clinical studies like ALIGN3D and MTA3D, where interim data on radiographic correction, recurrence, pain and patient‑reported outcomes are presented at orthopedic conferences. Investors can also see announcements about debt financing arrangements, investor conferences, investor days and changes in board composition or governance roles.
For investors, clinicians and analysts tracking TMCI stock, this news feed offers a consolidated view of Treace’s financial disclosures, product pipeline developments and market‑facing activities related to bunion and midfoot deformity surgery.
Treace Medical Concepts announced its participation in the Truist Securities MedTech Conference on June 18, 2024, at 8:00 am Eastern Time. CEO John T. Treace and CFO Mark L. Hair will join a fireside chat during the event. The discussion will be webcasted live and available for replay on Treace's investor relations website. Treace, known for its Lapiplasty® and Adductoplasty® Procedures, spearheads advancements in the surgical treatment of bunions and midfoot deformities.
Treace Medical Concepts, Inc. reported $51.1 million in revenue for Q1 2024, a 21% increase from the same period in 2023. Despite a net loss and revised guidance for 2024, the company achieved milestones, expanded its patent portfolio, and introduced new technologies. The CEO remains optimistic about navigating competitive challenges and delivering shareholder value.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.